PL2441767T3 - Salinosporamidy i sposoby ich stosowania - Google Patents

Salinosporamidy i sposoby ich stosowania

Info

Publication number
PL2441767T3
PL2441767T3 PL11163737T PL11163737T PL2441767T3 PL 2441767 T3 PL2441767 T3 PL 2441767T3 PL 11163737 T PL11163737 T PL 11163737T PL 11163737 T PL11163737 T PL 11163737T PL 2441767 T3 PL2441767 T3 PL 2441767T3
Authority
PL
Poland
Prior art keywords
salinosporamides
methods
Prior art date
Application number
PL11163737T
Other languages
English (en)
Inventor
William H Fenical
Paul R Jensen
Tracy J Mincer
Robert H R Feling
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/600,854 external-priority patent/US7179834B2/en
Priority claimed from US10/838,157 external-priority patent/US7176232B2/en
Application filed by Univ California filed Critical Univ California
Publication of PL2441767T3 publication Critical patent/PL2441767T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL11163737T 2003-06-20 2004-06-18 Salinosporamidy i sposoby ich stosowania PL2441767T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/600,854 US7179834B2 (en) 2002-06-24 2003-06-20 Salinosporamides and methods for use thereof
US10/838,157 US7176232B2 (en) 2002-06-24 2004-04-30 Salinosporamides and methods for use thereof
EP11163737.7A EP2441767B1 (en) 2003-06-20 2004-06-18 Salinosporamides and methods for use thereof
EP04776728A EP1638977A4 (en) 2003-06-20 2004-06-18 SALINOSPORAMIDES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
PL2441767T3 true PL2441767T3 (pl) 2015-11-30

Family

ID=36923797

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11163737T PL2441767T3 (pl) 2003-06-20 2004-06-18 Salinosporamidy i sposoby ich stosowania

Country Status (7)

Country Link
US (1) US8217072B2 (pl)
EP (1) EP2441767B1 (pl)
CN (2) CN1823070A (pl)
IL (1) IL172704A (pl)
NZ (1) NZ544858A (pl)
PL (1) PL2441767T3 (pl)
ZA (1) ZA200600473B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US8217072B2 (en) 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
DE602004031614D1 (de) * 2003-06-20 2011-04-14 Nereus Pharmaceuticals Inc Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
KR101282191B1 (ko) * 2004-12-03 2013-07-08 다나-파버 캔서 인스티튜트 인크. 신생물성 질환을 치료하는 조성물 및 방법
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
JP2011514352A (ja) 2008-03-07 2011-05-06 ネレアス ファーマシューティカルズ インコーポレイテッド サリノスポラミドａおよびその類似体の全合成
US20090285836A1 (en) * 2008-04-14 2009-11-19 Nereus Pharmaceuticals, Inc. Use of salinosporamide a to inhibit metastasis
AU2009246467A1 (en) 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5276182A (en) * 1990-07-09 1994-01-04 The Dow Chemical Company Process for preparing polyurea oligomers
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
EP1500393A1 (en) * 1992-11-27 2005-01-26 Mayne Pharma (USA) Inc. Injectable composition containing taxol
US5654286A (en) * 1993-05-12 1997-08-05 Hostetler; Karl Y. Nucleotides for topical treatment of psoriasis, and methods for using same
PT721335E (pt) * 1993-10-01 2005-11-30 Roche Palo Alto Llc Suspensoes orais em altas doses de micofenolato de mofetil
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US6335358B1 (en) * 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5667809A (en) * 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874443A (en) * 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) * 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
NZ337364A (en) 1997-02-15 2001-06-29 Millennium Pharm Inc Treatment of infarcts, ischemia and reperfusion through inhibition of NFkappaB
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
WO1999006353A1 (fr) * 1997-08-04 1999-02-11 Taisho Pharmaceutical Co., Ltd. Derives aryloxyaniline
BR9811304A (pt) 1997-08-15 2001-11-13 Francois Soucy Sìntese de clasto-lactacistina" beta"-lactona eseus análogos
US6133308A (en) * 1997-08-15 2000-10-17 Millennium Pharmaceuticals, Inc. Synthesis of clasto-lactacystin beta-lactone and analogs thereof
US20010051654A1 (en) * 1997-09-25 2001-12-13 Elliott Peter J. Treatment of inflammatory and autoimmune diseases
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
CA2310664C (en) * 1997-11-21 2008-03-11 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6333323B1 (en) * 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) * 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
BR9914648A (pt) 1998-10-20 2001-11-27 Millennium Pharm Inc Processo para monitorar ação medicamentosa deinibidor de proteasoma
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20020049157A1 (en) * 1999-08-25 2002-04-25 Jiangping Wu Use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
CA2425632A1 (en) * 2000-10-12 2002-04-18 Viromics Gmbh Agents for the treatment of viral infections
US7144723B2 (en) * 2000-11-16 2006-12-05 The Regents Of The University Of California Marine actinomycete taxon for drug and fermentation product discovery
DE10316735A1 (de) * 2002-04-05 2003-11-20 Viromics Gmbh Mittel zur Behandlung von Flaviviridae-Infektionen
US7179834B2 (en) * 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004043374A2 (en) 2002-11-06 2004-05-27 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating cancer using proteasome inhibitors
DE602004024037D1 (de) 2003-02-14 2009-12-24 Intermed Discovery Gmbh Substituierte heterozyklen
DE602004031614D1 (de) * 2003-06-20 2011-04-14 Nereus Pharmaceuticals Inc Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs
US8217072B2 (en) 2003-06-20 2012-07-10 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2005094423A2 (en) 2004-02-26 2005-10-13 President And Fellows Of Harvard College Selective inhibition of proteasomes of tuberculosis and other bacteria
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
US7183417B2 (en) * 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
JP2007535559A (ja) 2004-04-30 2007-12-06 ネレアス ファーマシューティカルズ インコーポレイテッド ［３．２．０］複素環式化合物及びその使用法
US7579371B2 (en) * 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US20060264495A1 (en) * 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
KR101282191B1 (ko) * 2004-12-03 2013-07-08 다나-파버 캔서 인스티튜트 인크. 신생물성 질환을 치료하는 조성물 및 방법
US20060287520A1 (en) * 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
WO2007030662A1 (en) * 2005-09-09 2007-03-15 Nereus Pharmaceuticals, Inc. Biosynthesis of salinosporamide a and its analogs
BRPI0618198A2 (pt) * 2005-11-04 2018-06-26 Nereus Pharmaceuticals Inc métodos de tratamento, prevenção ou inibição de câncer e de linfoma, composição, kit, e, método de tratamento de câncer resistente a terapia
GB0605217D0 (en) * 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
CN101460457B (zh) * 2006-04-06 2012-07-18 尼瑞斯药品公司 Salinosporamide a及其类似物的全合成
US8088923B2 (en) * 2006-07-07 2012-01-03 The Texas A&M University System Cyclic-fused beta-lactones and their synthesis
US20080280968A1 (en) * 2007-05-04 2008-11-13 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof for treating infectious diseases
US7442830B1 (en) * 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
JP2011514352A (ja) * 2008-03-07 2011-05-06 ネレアス ファーマシューティカルズ インコーポレイテッド サリノスポラミドａおよびその類似体の全合成
AU2009246467A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Salinosporamide derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
US20090318529A1 (en) 2009-12-24
CN1823070A (zh) 2006-08-23
ZA200600473B (en) 2007-04-25
NZ544858A (en) 2009-07-31
IL172704A0 (en) 2006-04-10
EP2441767A1 (en) 2012-04-18
US8217072B2 (en) 2012-07-10
CN101791306A (zh) 2010-08-04
IL172704A (en) 2016-02-29
EP2441767B1 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
EP1638977A4 (en) SALINOSPORAMIDES AND METHODS OF USE
ZA200603882B (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
HK1088837A1 (en) Clk-peptide and slk-peptide
IL172704A0 (en) Salinosporamides and methods for use thereof
GB0318546D0 (en) Quinoxalinones and their use
GB0300804D0 (en) Compounds and their use
GB0300805D0 (en) Compounds and their use
GB0301143D0 (en) Compounds and their use
HK1169120A1 (zh) 孢菌酰胺及其使用方法
SI2441767T1 (sl) Salinosporamidi in metode za njihovo uporabo
GB0329079D0 (en) Method and use
GB0309320D0 (en) Compounds and their use
GB0314295D0 (en) Compounds and their use
GB0302930D0 (en) Compounds and their use
GB0302933D0 (en) Compounds and their use
GB0304819D0 (en) Compounds and their use
GB0304820D0 (en) Compounds and their use
GB0309319D0 (en) Compounds and their use
GB0301146D0 (en) Compounds and their use
GB0310333D0 (en) Compounds and their use
GB0310470D0 (en) Compounds and their use
GB0310471D0 (en) Compounds and their use
GB0310472D0 (en) Compounds and their use
GB0311820D0 (en) Compounds and their use